In this section of the General Tradeshow News Site, you'll find event-related news releases from PR Newswire. The releases are listed in chronological order and are archived by month and year.
- Updated subgroup analysis in 34 heavily pretreated patients with HER2-low-expressing metastatic breast cancer demonstrated a 50.0 percent confirmed overall response rate and an 85.3 percent disease control rate with DS-8201
- First-in-human safety data presented from phase 1/2 study with U3-1402, an investigational and potential first-in-class HER3-targeting antibody drug conjugate (ADC), in patients with heavily pretreated HER3-positive metastatic breast cancer
Interim Phase IIb Data Show Promising Reduction In Risk of Recurrence and a Well-Tolerated Safety Profile in Patients with Resected, High-Risk Melanoma
R. A. RIAM GROUP'S PROVOCATIVE AND EXCITING NEW VENTURE CAPTURES THE NEVER-BEFORE-SEEN TECHNOLOGY AND ARTISANSHIP BEHIND THE JOURNEY OF A CREATED DIAMOND